Poly Medicure (531768) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
25 Sep, 2025Deal rationale and strategic fit
Acquisition provides entry into the fast-growing global orthopaedic trauma and extremity segment, a resilient $12 billion market expected to reach $16 billion, leveraging a differentiated, MDR-certified and patented product portfolio with strong positions in Italy, Mexico, and a growing U.S. presence.
The deal aligns with a strategy to expand into high-growth medical device segments, leveraging CTFE as a platform for global orthopedic expansion and accelerating growth in developed markets.
Integrated business model from R&D to distribution enables agile product development, rapid market entry, and strengthens innovation pipeline.
Direct sales presence in Italy, USA, and Mexico, with strong market positions in Italy and Mexico, supports global expansion ambitions.
Citieffe's strong R&D and patented portfolio align with the acquirer's mission to deliver innovative, patient-centric technologies.
Financial terms and conditions
100% equity acquired for €18.8 million, with €4.2 million shareholder loan repayment, totaling €23 million payout at closing; €8.1 million net external debt assumed, valuing the company at €31 million enterprise value (EV/EBITDA 10.2x FY24).
CTFE/Citieffe reported €17.3 million revenue and €3.1 million EBITDA in 2024, with gross margins exceeding 90% and YoY growth of 15% and 14%, respectively.
Net block stands at €5 million, with total historical investment around $30 million.
Funded by internal accruals and cash balances.
Synergies and expected cost savings
Immediate synergy from adding plates and joint replacement to the product portfolio, enabling participation in more public tenders and entry into new markets.
Potential to double CTFE's business in five years by leveraging distribution networks and expanding into new geographies.
Outsourcing manufacturing to India expected to reduce costs, improve margins, and build a direct sales unit for CTFE products in India.
Synergies expected from integrating distribution networks and local manufacturing to enhance competitiveness and lower costs.
Expansion of distribution in markets where CTFE currently lacks presence.
Latest events from Poly Medicure
- Global expansion, innovation, and acquisitions drive strong growth and margin gains.531768
Investor presentation9 Mar 2026 - Double-digit revenue growth and margin strength driven by expansion and innovation.531768
Q3 25/266 Feb 2026 - Q3 FY25 revenue up 24.9% YoY, margins and cash position strong, growth outlook robust.531768
Q3 24/253 Feb 2026 - Q1 revenue and EBITDA up 20%, EPS rises, exports surge, and capacity expansion drives growth.531768
Q1 24/253 Feb 2026 - H1 FY25 saw 23% revenue growth, 28.06% EBITDA margin, and robust QIP-driven expansion.531768
Q2 24/2518 Jan 2026 - FY25 revenue rose 21.5% with margin gains, QIP capital raised, and a ₹3.50 dividend recommended.531768
Q4 24/257 Jan 2026 - Q1 FY26 delivered strong revenue and profit growth, led by domestic momentum and innovation.531768
Q1 25/266 Jan 2026 - FY26 guidance revised to 15%-16% growth, strong margins, and major European acquisitions.531768
Q2 25/2610 Nov 2025 - Acquisition of a European cardiology consumables group accelerates global expansion and synergies.531768
M&A Announcement4 Sep 2025